L1 Capital Global Opportunities Master Fund, Ltd. 13D and 13G filings for BriaCell Therapeutics Corp.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-11 5:47 pm Sale |
2021-12-31 | 13G | BriaCell Therapeutics Corp. BCTX |
L1 Capital Global Opportunities Master Fund, Ltd. | 7,000 11.000% |
-59,667 (-89.50%) |
Filing |
| 2021-03-05 4:13 pm Purchase |
2021-02-26 | 13G | BriaCell Therapeutics Corp. BCTX |
L1 Capital Global Opportunities Master Fund, Ltd. | 66,667 16.300% |
66,667 (New Position) |
Filing |